Increasing ambulatory activity reduces cardiovascular events in patients with impaired glucose tolerance and raised risk, data from the Navigator trial has shown. The main objective of the original study was to determine whether valsartan or nateglinide prevented cardiovascular events and/or progression of impaired glucose tolerance to overt diabetes. The findings did not show any protective effect from either drug. However, as well as the original research question posed by the trial, the cohort provided a large amount of prospective data for further analysis.  The current paper analysed the relationship between change in daily ambulatory activity and cardiovascular events.